alnylam development pipeline hereditary attr amyloidosis with polyneuropathy hattr pn hereditary attr amyloidosis with cardiomyopathy hattr cm hemophilia complement mediated disease porphyria cardio metabolic disease alpha 1 antitrypsin deficiency hepatitis b virus beta thalassemia other pipeline programs who we are our story our culture management board operating team board of directors scientific advisory board corporate overview patients alnylam clinical trials about clinical trials alnylam assist patient connect access to investigational drugs careers at alnylam investors contact capella legal information privacy policy menu skip to content home patients alnylam clinical trials about clinical trials free third party generic screening and counseling programs patient connect e mail alert sign up access to investigational drugs investors overview stock information corporate governance sec filings fundamentals shareholder information earnings estimates ownership profile online investor kit press releases annual meeting events search investor relations careers contact capella presentations roundtables publications media kit glossary alnylam our approach product pipeline who we are about alnylam about rnai delivery of rnai therapeutics scientific leadership strategic alliances intellectual property menugenetic medicine strategic therapeutic area star hereditary attr amyloidosis with polyneuropathy hattr pn hereditary attr amyloidosis with cardiomyopathy hattr cm hemophiliacomplement mediated diseaseporphyriaprimary hyperoxaluriabeta thalassemiaalpha 1 antitrypsin deficiency closecardio metabolic disease strategic therapeutic area star hypercholesterolemiamixed hyperlipidemia closehepatic infectious disease strategic therapeutic area star hepatitis b virushepatitis d viruschronic liver infection close our story our culture our commitment careers management board operating team board of directors scientific advisory board 1 . possibility to patients 2 . alnylam s clinical trials 3 . career opportunities 4 . alnylam s science 5 . investor relations click here for more information aboutalnylam s ongoing clinical trials alnylam pharmaceuticalsdiscontinues revusiran development 07.19.2016 2016 rnai roundtable series we are hosting a series of online rnai roundtables in which alnylam scientists and key clinical collaborators review recent progress in many of the company s development stage pipeline programs and discuss the related disease areas . click here to access our current and previous presentations . 09.28.2016 clinical data from aln aat and non clinical research demonstrating continued rnai platform optimization and leadership in the field we presented clinical and non clinical data in a series of posters and oral presentations at the 12th annual meeting of the oligonucleotide therapeutics society ots held september 25 28 2016 in montreal quebec . read our press release view the aln aat phase 1 2 presentation 670 kb pdf view the poster on review of non clinical safety data for galnac sirnas 2 mb pdf view the poster on galnac sirna vs. galnac aso 2 mb pdf view the poster on cholesterol conjugates for muscle delivery 620 kb pdf read more 09.24.2016 initial results from ongoing phase 1 2 study with aln go1 in development for the treatment of primary hyperoxaluria type 1 we presented initial clinical data from aln go1 an investigational rnai therapeutic targeting glycolate oxidase go for the treatment of primary hyperoxaluria type 1 ph1 at the 17th congress of the international pediatric nephrology association ipna held september 20 24 2016 in igua u brazil . read our press release view the presentation 970 kb pdf read more 09.14.2016 pre clinical results from aln cc5 for the treatment of complement mediated diseases we reported new pre clinical results in animal models of myasthenia gravis mg from aln cc5 an investigational rnai therapeutic in development for the treatment of complement mediated diseases at the american association of neuromuscular & electrodiagnostic medicine aanem annual meeting held september 14 17 in new orleans louisiana . view the presentation 1 mb pdf read more world hepatitis day july 28th is world hepatitis day a day since 2010 the world health organization who has set as one of only four official disease specific world health days . world hepatitis day is celebrated each year with the goal to bring awareness about viral hepatitis to call for patient access to the best treatments better prevention programs and government action to eradicate this disease as a public health threat by 2030 . learn more alnylam pharmaceuticals supports greater boston and norton communities with its 2nd annual helping hands community service day on june 23 over 400 alnylam employees participated in its second annual company wide helping hands community service day to benefit ten local non profit organizations including boston nature center cradles to crayons emerald necklace conservancy friends of alewife habitat education center imec america cupboard of kindness norton conservation land west end house boys and girls club and windrush farms . read the article on thursday april 28 2016 alnylam broke ground for its new manufacturing facility in norton massachusetts an exciting next step in alnylam s journey to patients . watch the webcast behind the mystery rare & genetic series ttr amyloid battling a rare medical condition that s often misdiagnosed.imagine having a rare debilitating disease that s passed down through families . dr. john berk associate professor of medicine at boston university and clinical director of its amyloidosis center joins us to discuss the medical condition called transthyretin mediated amyloidosis . it s symptoms are similar to other conditions and attr patients are very often misdiagnosed . we discuss symptoms family connections and treatment options in this behind the mystery rare & genetic segment . and meet dylan duncan who s battling the disease . you don t want to miss this . watch the video search search featured news more news events 2016 rnai roundtable aln hbv for the treatment of hepatitis b virus hbv infection tuesday october 11 2016 9 00 am et leerink partners rare disease & immuno oncology roundtable wednesday september 28 2016 1 35 pm et 2016 rnai roundtable aln go1 for the treatment of ph1 tuesday september 27 2016 10 00 am et investors nasdaq alny common price change % % volume minimum 20 minute delay learn more follow us follow us for recent news happenings and career opportunities . follow alnylam twitter linkedin youtube copyright 2016 alnylam pharmaceuticals inc. all rights reserved glossary media kit legal privacy policy site map